uniQure (QURE) Expected to Announce Quarterly Earnings on Wednesday

uniQure (NASDAQ:QURE) is expected to be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $18.45 million for the quarter.

uniQure Trading Down 0.9 %

QURE opened at $12.84 on Monday. The stock has a fifty day moving average price of $15.50 and a 200-day moving average price of $9.66. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The firm has a market cap of $625.86 million, a price-to-earnings ratio of -2.59 and a beta of 0.39.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.74% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have commented on QURE. StockNews.com raised uniQure to a “sell” rating in a research report on Wednesday, February 5th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. HC Wainwright increased their price target on uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a report on Monday, January 27th. Mizuho upped their price target on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. Finally, Cantor Fitzgerald boosted their target price on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.00.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.